47 results about "Growth Factor Gene" patented technology

The invention discloses a tissue engineered bone compound which comprises porous perforated between aperture artificial bone bracket and mesenchymal stem cells implanted in hole and transfected with vascular endothelial growth factor gene. The invention also discloses the application of the tissue engineered bone compound as material for bone defect repair. The inventive tissue engineered bone compound can make seed cell exert osteogenesis, express and secrete VEGF, thereby promoting vasal formation and growth, providing material basis for new bone formation, in favor of neogenesis of vascularized tissue engineered bone tissue, improving effect for repairing bone defect.

The invention belongs to the field of biotechnology, especially the detection of gene mutation. More specifically, the invention discloses 9 groups of primers for detection of 41 mutation of a human epidermal growth factor EGFR gene and a detection method by using the primers.

The invention discloses a construction method and a purpose of recombinant lactobacillus acidophilus expressing pig epidermal growth factors. Primers containing specific enzyme cutting sites are designed according to disclosed gene sequences and expression vector plasmid characteristics of the pig epidermal growth factors; pig lower jaw glandular tissues are taken as the material, a segment containing pig epidermal growth factor genes is obtained through a reverse transcription-polymerase chain reaction (RT-PCR), and the segment is connected with a lactobacillus expression vector plasmid pMG36e to obtain a recombinant plasmid pMG36e-egf, the recombinant plasmid is placed into lactobacillus acidophilus with an electrotransformation method to obtain the recombinant lactobacillus acidophilus expressing the pig epidermal growth factors, expression is performed under the induction of nisin, and correct expression of target genes is proved through sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and western blot. The recombinant lactobacillus acidophilus is used for preventing diarrhea occurrence, improving intestinal tract health of pigs and promoting growth performance.

The present invention provides compositions and methods for modulating the expression of growth factor gene. In particular, this invention relates to compounds, particularly oligonucleotide compounds, which, in preferred embodiments, hybridize with nucleic acid molecules encoding the Insulin Like Growth Factor I receptor (IGF-I receptor or IGF-IR) and in particular human IGF-IR. Such compounds are exemplified herein to modulate proliferation which is relevant to the treatment of proliferative and inflammatory skin disorders and cancer. It will be understood, however, that the compounds can be used for any other condition in which the IGF-IR is involved including inflammatory conditions.

The present invention provides one kind of pig's epidermal growth factor gene with the nucleotide sequence shown in SEQ ID No. 1 of the sequence list. The present invention provides also the gene engineering bacterium C32 containing 14 copies of the gene, and the gene engineering bacterium has high pEGF expressing amount, simple purifying process and low production cost. The present invention makes it possible to produce pig's epidermal growth factor gene in industrial scale.

The present invention provides a composite fiber which comprises an alginate fiber, a polymer material, an antibacterial agent, and a plasmid encoding growth factor-gene. The present invention also provides a wound dressing, wherein the wound dressing comprises a composite fiber as described above. The composite fibers prepared according to the present invention are capable of releasing the antibacterial agent and the growth factor gene, not only to reduce microorganism growth, but also to secrete growth factors in a wound site through transfection, thereby promoting wound healing.

The invention discloses an artificial porcine epidermal growth factor eukaryotic expression vector and a preparation method and brewers yeast engineering bacteria thereof. A porcine epidermal growth factor gene is artificially synthesized according to the preference of brewers yeast to a porcine epidermal growth factor codon, and is shown as SEQ ID NO. 1 in a sequence table. The invention further provides a brewers yeast expression vector containing the gene and engineering bacteria with secretory expression of the gene, and further provides a method for obtaining the engineering bacteria. The artificial porcine epidermal growth factor gene has preference to the brewers yeast; the engineering bacteria of the gene have a brewers yeast signal peptide which is favorable for the secretory expression of the porcine epidermal growth factor and is induced by raffinose which can be used as feed instead of methanol during expressing the porcine epidermal growth factor; and the engineering bacteria and the expressed product can be directly used as feed without being purified and extracted, so that the cost and growth period of the porcine epidermal growth factor as feed are greatly reduced, and the application of the porcine epidermal growth factor in the feed industry becomes possible.

This invention provides alternative bone implants that have high bioadaptability and enable rapid bone regeneration. Specifically, this invention relates to implants consisting of a bioadaptable material comprising cells transfected with growth factor genes. Such implants are produced by inoculating bone-marrow-derived cells transfected with the genes of vascular endothelial growth factors (VEGF) into a bioadaptable material, such as porous ceramics, and culturing them.

This invention relates to compounds, compositions, and methods useful for modulating placental growth factor (e.g., PGF-1 or PlGF-1, PGF-2 or PlGF-2, and/or PGF-3 or PlGF-3) gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of placental growth factor gene expression and/or activity by RNA interference (RNAi) using small nucleic acid molecules. In particular, the instant invention features small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules and methods used to modulate the expression of placental growth factor genes.

The invention provides an encoding gene of a recombinant insulin-like growth factor, lactobacillus containing the encoding gene and application of the lactobacillus, and belongs to the field of bio-genetic engineering. The insulin-like growth factor is a multifunctional cell proliferation regulation factor, has important acceleration in differentiation, proliferation, and growth and development of cells, but has the problems of insufficient throughout, high price, required purification of product, difficult drug administration and the like just as most of genetic engineering drugs. In order to obtain a lot of recombinant insulin-like growth factors, recombinant insulin-like growth factor genes optimized by codons are subjected to heterologous expression by adopting a lactobacillus expression system, and the recombinant lactobacillus is utilized as a living bacteria agent or a feed additive to enhance the nonspecific immunity of a pig.

The invention discloses a brassica napobrassica growth regulatory factor gene GRF2 and an application thereof. A base sequence of the gene is a nucleotide sequence represented by SEQ ID NO:1; or a gene sequence of another crop, wherein the gene sequence has no less than 70% homology with that represented by SEQ ID NO:1; or a mutant allele or a derivative obtained after one or more nucleotides areprocessed through addition, substitution, insertion or deletion. As a result of researches, the expression level of the gene in brassica napobrassica high-oil parents and high-oil mixture crops is higher than that in low-oil parents and low-oil mixture crops. A transgene result obtained by using arabidopsis thaliana as an acceptor verified that, with the over-expression of the gene, arabidopsis thaliana oil content is improved, and a 1000-seed weight of arabidopsis thaliana is increased. The invention also provides an application of brassica napobrassica growth regulatory factor gene BnGRF2 in improving the 1000-seed weight and oil content of plants such as arabidopsis thaliana. Therefore, the gene has good application prospect in oil-yield seed breeding of brassica napobrassica and otheroil crops.

The invention relates to a cell growth factor gene drug for preventing and/or treating acute stress-related gastrointestinal injury, and use of HIF-1 alpha and KGF genes in preparing drugs for preventing and/or treating acute stress-related gastrointestinal injury diseases. The invention also relates to a pharmaceutical composition comprising HIF-1 alpha and KGF. The growth factor gene drug provided by the invention can beneficially prevent and/or treat acute stress-related gastrointestinal injury diseases.

The invention provides functions of imaginal disk growth factors (IDGF) and an application of dsRNA of the imaginal disk growth factors. The imaginal disk growth factors can assist insects to resist germ invasion. When the imaginal disk growth factors keep silent by the dsRNA, the resistibility of the insects is reduced until the insects die. After the imaginal disk growth factor gene of black cutworms is subjected to cloning and sequencing, the obtained sequence is as shown in SEQID NO:1; on the base of the obtained sequence, a fragment of which the sequence is as shown in SEQID NO:2 is selected and is used for synthesis of double-strand RNA(dsRNA); and after the dsRNA is injected into the body cavities of the insects, the phenomena that the resistibility is reduced, the insects are susceptible to germs and melanism appears are presented in the development process of the insects, and the mortality rate is greatly raised. The imaginal disk growth factors disclosed by the invention provide a new target for pest control.

The invention relates to biology and medicine fields, concretely, relates to application of liver cell growth factor in preventing and treating tissue accretion. The invention inserts human hepatocyte growth factor full-length coding region cDNA into plasmid carrier (pc DNA 3 or p UDK or others), or into adenovirus carrier (such as Ad5 or gutless adenovirus) to obtain recombinant plasmid or recombinant adenovirus of the human hepatocyte growth factor gene. The recombinant plasmid or recombinant adenovirus can prevent and cure postoperative intestinal adhesion or pelvic cavity adhesion or other tissue adhesion by being locally painted on abdominal cavity or pelvic cavity. Thus, the recombinant plasmid or recombinant adenovirus carrying the human hepatocyte growth factor gene has excellent application prospect on prevent-curing or treatment for postoperative tissue adhesion.

The invention discloses a method for obtaining a polyclonal antibody of a sheep independent growth factor 1B, which comprises the following steps: performing PCR (polymerase chain reaction) amplification on a sheep independent growth factor 1B gene by using a designed specific primer GFI-1, thus obtaining a CDS sequence thereof; performing enzyme cutting by using a specific primer GFI-2, and constructing a prokaryotic expression vector, thus obtaining the prokaryotic expression vector pET32a-GFI1B; performing target gene induced expression on the prokaryotic expression vector pET32a-GFI1B, thus obtaining a sheep independent growth factor 1B protein; purifying the sheep independent growth factor 1B protein to 85% or above; immunizing the purified sheep independent growth factor 1B protein onto an animal, collecting whole blood one week after the last immunization, and separating the blood serum; and purifying the blood serum, thus obtaining the polyclonal antibody of the target sheep independent growth factor 1B gene.

The present invention provides compositions and methods for modulating the expression of growth factor gene. In particular, this invention relates to compounds, particularly oligonucleotide compounds, which, in preferred embodiments, hybridize with nucleic acid molecules encoding the Insulin Like Growth Factor I receptor (IGF-I receptor or IGF-IR) and in particular human IGF-IR. Such compounds are exemplified herein to modulate proliferation which is relevant to the treatment of proliferative and inflammatory skin disorders and cancer. It will be understood, however, that the compounds can be used for any other condition in which the IGF-IR is involved including inflammatory conditions.

The invention provides application of a human hepatocyte growth factor gene in eczema treatment and a microneedle medical instrument. The human hepatocyte growth factor gene is constructed into an eukaryotic expression vector, a virus vector and a gene expression cassette or minicircle DNA (Deoxyribose Nucleic Acid), and can obviously play a role in resisting eczema and related symptoms after being locally introduced subcutaneously by adopting a microneedle or injection mode and the like. Therefore, the human hepatocyte growth factor gene has an extremely good application prospect in the aspect of eczema treatment, and especially in the form of a microneedle instrument, not only can the eczema symptom be inhibited, but also the side effect is small.

The present invention relates to a recombinant plasmid with human hepatocyte growth factor gene and its application for preventing and curing diseases. The human hepatocyte growth factor gene is inserted into pUDK plasmid vector to obtain recombinant plasmid pUDKH. After said recombinant plasmid is transferred into ischemic region of rat or rabbit member by means of local intramuscular injection or gene gun method, said recombinant plasmid can effectively express and obviously promote vascularization. Said recombinant plasmid can be applied to surface of wound of rabbit ear of transferred into wound position by means of gene gun, it possesses the function of preventing and curing scar, so that aid recombinant plasmid possesses good application for preventing and curing ischmic diseases and pathological scar.